<div id="readability-page-1"><p>Oppenheimer &amp; Co. Inc. purchased a new position in shares of  Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,076 shares of the company's stock, valued at approximately $1,292,000.</p><ul><li>Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out</li></ul><p>Other large investors have also bought and sold shares of the company. M&amp;T Bank Corp lifted its holdings in shares of  Axsome Therapeutics by 37.3% in the fourth quarter. M&amp;T Bank Corp now owns 2,560 shares of the company's stock worth $467,000 after acquiring an additional 696 shares during the last quarter.  Pictet Asset Management Holding SA increased its position in  Axsome Therapeutics by 20.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company's stock worth $79,643,000 after purchasing an additional 73,925 shares in the last quarter.  UBS Group AG lifted its stake in  Axsome Therapeutics by 67.2% in the 4th quarter. UBS Group AG now owns 355,318 shares of the company's stock valued at $64,895,000 after purchasing an additional 142,867 shares during the last quarter.  Concurrent Investment Advisors LLC acquired a new stake in  Axsome Therapeutics in the fourth quarter valued at approximately $300,000.  Finally, HB Wealth Management LLC grew its stake in shares of  Axsome Therapeutics by 136.7% during the fourth quarter. HB Wealth Management LLC now owns 34,102 shares of the company's stock worth $6,228,000 after buying an additional 19,696 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds. </p><div><p><span></span><span>Get <strong>Axsome Therapeutics</strong> alerts:</span></p></div><h2>Axsome Therapeutics News Roundup</h2><p>Here are the key news stories impacting Axsome Therapeutics this week:</p><ul>   <li><span>Positive Sentiment: </span>Strong commercial traction — Axsome reported Q1 product revenue of $191.2M, up ~57% year‑over‑year driven by AUVELITY and SUNOSI, which supports the company’s growth narrative and near‑term cash generation. Read More.</li>    <li><span>Positive Sentiment: </span>Analyst optimism and price‑target lifts — multiple firms raised targets (notably Mizuho to $310, Wells Fargo to $255, Baird and others), and coverage remains skewed positive, which can support upside momentum and bid interest. Read More.</li>    <li><span>Neutral Sentiment: </span>Management outreach scheduled — Axsome will participate in May investor conferences (including a BofA fireside chat), offering additional investor access but uncertain immediate impact. Read More.</li>    <li><span>Neutral Sentiment: </span>Earnings detail and call transcript available — analysts are parsing the conference call and guidance implications; deeper read may resolve questions around sales cadence and expense trajectory. Read More.</li>    <li><span>Negative Sentiment: </span>Profitability miss — GAAP EPS of ($1.26) missed consensus (~$0.85 loss), and negative margins/ROE highlight near‑term profitability and cost structure concerns despite revenue strength. Read More.</li>    <li><span>Negative Sentiment: </span>Insider selling — COO Mark Jacobson disclosed sales (large blocks on May 4 and a smaller sale May 5), which may raise short‑term sentiment questions even though filers report remaining holdings. Read More.</li>    <li><span>Negative Sentiment: </span>Durability concerns — some analysts/commentators question sequential product sales trends and achievability of peak revenue assumptions, which could temper multiple expansion absent clearer margin improvements. Read More.</li> </ul><h2>Analyst Ratings Changes</h2><ul><li>5 medical stocks growing earnings by triple digits</li></ul><p>Several research firms recently weighed in on AXSM. Jefferies Financial Group raised their price objective on Axsome Therapeutics from $245.00 to $275.00 and gave the company a &#34;buy&#34; rating in a report on Monday. Cantor Fitzgerald  reissued an &#34;overweight&#34; rating and set a $272.00 price target on shares of Axsome Therapeutics in a research note on Monday. Truist Financial raised Axsome Therapeutics to a &#34;strong-buy&#34; rating in a research note on Wednesday, March 25th. Oppenheimer  set a $280.00 target price on shares of Axsome Therapeutics in a research report on Monday. Finally, Needham &amp; Company LLC boosted their target price on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday. One research analyst  has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $251.26.</p><p><b>View Our Latest Stock Report on AXSM</b></p><h2>Axsome Therapeutics Trading Down 0.2%</h2><ul><li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li></ul><p>NASDAQ:AXSM opened at $222.63 on Thursday. Axsome Therapeutics, Inc. has a 52 week low of $96.09 and a 52 week high of $234.29. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.48 and a current ratio of 1.39. The firm's fifty day moving average is $172.69 and its 200-day moving average is $164.03. The firm has a market cap of $11.46 billion, a P/E ratio of -59.69 and a beta of 0.59. </p><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). The firm had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.Axsome Therapeutics's revenue was up 57.4% compared to the same quarter last year.  Equities analysts expect that  Axsome Therapeutics, Inc. will post -1.19 earnings per share for the current year. </p><h2>Insider Transactions at Axsome Therapeutics</h2><p>In other news, insider Ari Maizel sold 7,500 shares of the business's stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total value of $1,368,150.00. Following the transaction, the insider directly owned 7,500 shares of the company's stock, valued at $1,368,150. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, COO Mark L. Jacobson sold 35,378 shares of the company's stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $161.88, for a total value of $5,726,990.64. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 72,628 shares of company stock valued at $12,205,662. Corporate insiders own  20.60% of the company's stock. </p><h2>About Axsome Therapeutics</h2> (Free Report)<p>Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.  </p><p>Axsome's pipeline includes several late-stage and approved product candidates.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Axsome Therapeutics</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AXSM

<p>Oppenheimer & Co. Inc. has acquired a new position in Axsome Therapeutics, purchasing 7,076 shares valued at approximately $1.29 million in the fourth quarter. Other investors, including M&T Bank Corp and UBS Group AG, have also increased their stakes in the company. Despite strong revenue growth, Axsome faces challenges such as a profitability miss and insider selling, which may affect investor sentiment. Analysts remain optimistic, with several raising price targets and maintaining positive ratings on the stock, which has a consensus rating of "Moderate Buy."</p>

Market Beat

Axsome Therap

Oppenheimer

M&T Bank

UBS Group AG

Mizuho Financial

Mizuho Financial Group, Inc.

Wells Fargo

Bank of America

Jefferies Financial

Truist Financial

M & T BANK CORP DEP SHS REPSTG 1/400TH INT PERP SER K

M & T BANK CORP PERP NON CUM PFD FIXED FLTG RATE SER H

M & T BANK CORP DEP SHS EA REP 1/400TH SHS SERIES J

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Oppenheimer & Co. Inc. Takes $1.29 Million Position in Axsome Therapeutics, Inc. $AXSM